Dianthus Therapeutics Files 8-K for Disclosure
Ticker: DNTH · Form: 8-K · Filed: Jun 6, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Dianthus Therapeutics filed an 8-K on 6/6/24 for disclosures. Nothing major, just standard reporting.
AI Summary
Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) filed an 8-K on June 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware, is located in Cambridge, MA, and operates in the Pharmaceutical Preparations industry. Its principal executive offices are located at 7 Times Square, New York, NY.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and exhibits, which provides transparency to investors about the company's current status and operations.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for disclosures and financial statements, not indicating any significant new risks or events.
Key Numbers
- 001-38541 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-0724163 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Magenta Therapeutics, Inc. (company) — Former Name
- June 6, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Cambridge, MA (location) — Business Address City/State
- 7 Times Square, 43rd Floor, New York, New York, 10036 (location) — Address of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What was Dianthus Therapeutics, Inc. formerly known as?
Dianthus Therapeutics, Inc. was formerly known as Magenta Therapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 6, 2024.
Where are Dianthus Therapeutics, Inc.'s principal executive offices located?
Dianthus Therapeutics, Inc.'s principal executive offices are located at 7 Times Square, 43rd Floor, New York, New York, 10036.
What is the Standard Industrial Classification code for Dianthus Therapeutics, Inc.?
The Standard Industrial Classification code for Dianthus Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-06 08:00:49
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
Filing Documents
- dnth-20240606.htm (8-K) — 45KB
- dnth-ex99_1.htm (EX-99.1) — 28KB
- dnth-ex99_1s1.jpg (GRAPHIC) — 462KB
- dnth-ex99_1s2.jpg (GRAPHIC) — 600KB
- dnth-ex99_1s3.jpg (GRAPHIC) — 497KB
- dnth-ex99_1s4.jpg (GRAPHIC) — 555KB
- dnth-ex99_1s5.jpg (GRAPHIC) — 428KB
- dnth-ex99_1s6.jpg (GRAPHIC) — 442KB
- dnth-ex99_1s7.jpg (GRAPHIC) — 537KB
- dnth-ex99_1s8.jpg (GRAPHIC) — 467KB
- dnth-ex99_1s9.jpg (GRAPHIC) — 395KB
- dnth-ex99_1s10.jpg (GRAPHIC) — 144KB
- dnth-ex99_1s11.jpg (GRAPHIC) — 492KB
- dnth-ex99_1s12.jpg (GRAPHIC) — 437KB
- dnth-ex99_1s13.jpg (GRAPHIC) — 470KB
- dnth-ex99_1s14.jpg (GRAPHIC) — 380KB
- dnth-ex99_1s15.jpg (GRAPHIC) — 131KB
- dnth-ex99_1s16.jpg (GRAPHIC) — 331KB
- dnth-ex99_1s17.jpg (GRAPHIC) — 375KB
- dnth-ex99_1s18.jpg (GRAPHIC) — 344KB
- dnth-ex99_1s19.jpg (GRAPHIC) — 499KB
- dnth-ex99_1s20.jpg (GRAPHIC) — 427KB
- dnth-ex99_1s21.jpg (GRAPHIC) — 111KB
- dnth-ex99_1s22.jpg (GRAPHIC) — 416KB
- dnth-ex99_1s23.jpg (GRAPHIC) — 530KB
- dnth-ex99_1s24.jpg (GRAPHIC) — 111KB
- dnth-ex99_1s25.jpg (GRAPHIC) — 367KB
- dnth-ex99_1s26.jpg (GRAPHIC) — 430KB
- dnth-ex99_1s27.jpg (GRAPHIC) — 641KB
- 0000950170-24-069675.txt ( ) — 15408KB
- dnth-20240606.xsd (EX-101.SCH) — 55KB
- dnth-20240606_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Beginning on June 6, 2024, spokespersons of Dianthus Therapeutics, Inc. (the "Company") plan to present information contained in an updated corporate presentation (the "Presentation") at various meetings with investors and analysts. Marino Garcia, the Company's President and Chief Executive Officer, will also present the information in the Presentation at the Jefferies Global Healthcare Conference on June 6, 2024. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward-Looking Statements. The Presentation contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the Presentation regarding these forward-looking statements.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation of Dianthus Therapeutics, Inc., dated June 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: June 6, 2024 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary